Claim: Aveo Oncology to end breast cancer study due to low enrollment.
Verdict: SUPPORTS

Retrieved passages:
title: Avera Health
text: protocol for women age 41 and over with early stage breast cancer that delivers electron-based intraoperative radiation therapy (IORT) at the time of lumpectomy followed by three weeks of external beam radiation therapy, shortening follow-up external beam radiation therapy by three weeks. A new protocol is testing one-time IORT treatment for patients age 60 and over, eliminating the need for additional radiation. Avera is home to the region’s longest standing kidney transplant program, established in 1993, in addition to pancreas and liver transplant. In 1996, Avera began the region’s only Bone Marrow Transplant program, providing both allogeneic and autologous stem

title: Cancer prevention
text: - Reagan signs Medicare Catastrophic Coverage Act (mammography screenings) 1989 - MB-CCOP (minority-based community clinical oncology program) In the 1990s, many chemopreventative clinical trials began recruiting. Often, these studies lasted for more than a decade, so their results would be released in the early 2000s. 1991 - Chemoprevention (synthetic and natural) studies, DCPC + Produce for Better Health Foundation begins 5-A-Day message (fruit and veggie daily servings), ASSIST (smoking) initiative 1992 - Breast Cancer Prevention Trial (BCPT) 1993 - NCI mammography guidelines are dropped (controversy?), prostate lung colorectal, and ovarian cancer screening trial begins (PLCO), FOBT test for CRC mortality,

title: Cancer prevention
text: CAPS (colorectal adenoma prevention), enrollment for prostate cancer trial, NCI international breast cancer screening workshop 1994 - ATBC results show causal relationship between beta-carotene and lung cancer incidence in male Fins 1996 - ASCUS/LSIL Triage Study (HPV testing) 1997 - DCP and DCCPS splits from DCPC 1998 - Tamoxifen decreases breast cancer (Fisher?) 1999 - EDRN (early detection research network) and RAPID (access to prevention) established 1999 - Tamoxifen and raloxifene (STAR) clinical trials began, APC (adenoma celecoxib trial) Due to technological advancements, improved detection of biomarkers, and increased public and governmental support for cancer prevention research, the 21st century

title: Study of Tamoxifen and Raloxifene
text: cancer. Study of Tamoxifen and Raloxifene The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease. One of the largest breast cancer prevention studies ever, it included 22,000 women in 400 medical centers in the United States and Canada. The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen. Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive

title: Study of Tamoxifen and Raloxifene
text: Study of Tamoxifen and Raloxifene The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease. One of the largest breast cancer prevention studies ever, it included 22,000 women in 400 medical centers in the United States and Canada. The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen. Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive breast

title: Talazoparib
text: to expand their global oncology franchise. Medivation acquired talazoparib for $410 million with additional payments of up to $160 million in royalties and milestones. Under this agreement, Medivation assumed all financial responsibilities for the continued development, regulatory, and commercialization of talazoparib. As of January 2016, talazoparib is in 14 active clinical trials including a new arm of I-SPY 2. These trials cover a variety of cancers types and combination therapies. The most notable clinical trials are the ABRAZO and EMBRACA studies. ABRAZO is a phase II study for the safety and efficacy of treatment of BRCA breast cancer patients with

title: Carlos Arteaga
text: Science Center. Arteaga joined the faculty at Vanderbilt in 1989 and since 2002, has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE). Arteaga is recognized as an expert in the field of breast cancer research. He has demonstrated the utility of targeting TGF-β, which causes cancer to spread, metastasize, and become resistant to chemotherapeutic drugs. He was involved in the development of trastuzumab in combination with chemotherapy for patients with HER2-mutated cancer. Among his current research areas is triple-negative breast cancer, for which there are no targeted therapy options. He is a principal investigator for the

title: Risk factors for breast cancer
text: advanced stages and larger tumors) compared with cancers occurring in the placebo group, and HRT was also associated with a substantial increase in abnormal mammograms. Short-term use of hormones for treatment of menopausal symptoms appears to confer little or no breast cancer risk. A correlation was found between the use of hormonal contraceptives and subsequent reliance on hormone replacement therapy. Prophylactic oophorectomy (removal of ovaries) and mastectomy in individuals with high-risk mutations of BRCA1 or BRCA2 genes reduces the risk of developing breast cancer as well as reducing the risk of developing ovarian cancer. Because of a complex balance of

title: Talazoparib
text: talazoparib monotherapy. This study is for patients who have failed at least two prior chemotherapy treatments for metastatic breast cancer or been previously treated with a platinum regimen. The original target enrollment for the study was 70 patients but Biomarin expanded the trial to 140 patients. The estimated completion date is December 2016. EMBRACA is a phase III study for the treatment of BRCA breast cancer patients with talazoparib. This trial is an open-label, randomized, parallel, 2-arm, multi-center comparison of talazaporib against physician’s preference for the treatment of patients with locally advanced or metastatic breast cancer. Patients must also have

title: American Cancer Society Cancer Action Network
text: low-income women between 50 and 64 who are at most risk to breast and cervical cancer. This includes uninsured, underinsured, and racial and ethnic minority women. Services provided under NBCCEDP include clinical breast examinations, mammograms, pap smears, pelvic examinations, diagnostic testing for abnormal results, and treatment referrals. Since 1991, the program has provided more than 9.8 million breast and cervical cancer screenings, and diagnosed more than 52,694 breast cancers, 2,856 invasive cervical cancers, and 136,837 premalignant cervical lesions. ACS CAN works to reauthorize and increase funding for NBCCEDP since it has been at risk for recent budget cuts. Although NBCCEDP

title: Hormone replacement therapy
text: when using estrogen. They were given either placebo or CEEs alone. This group did not show the risks demonstrated in the combination hormone study, and the estrogen-only study was not halted in 2002. However, in February 2004 it, too, was halted. While there was a 23% decreased incidence of breast cancer in the estrogen-only study participants, risks of stroke and pulmonary embolism were increased slightly, predominantly in patients who began HRT over the age of 60. The WHI trial was limited by low adherence, high attrition, inadequate power to detect risks for some outcomes, and evaluation of few regimens. The

title: Vaccinogen
text: The Primary Endpoint in this study is the Disease-Free Interval. Vaccinogen plans to conduct a pilot program in parallel with ACTIVE to evaluate OncoVAX in combination with an adjuvant chemotherapy treatment for stage III colon cancer patients. In September 2015 Vaccinogen announced an exclusive two-year option with Dublin City University over a high-throughput, multiplex, analysis platform developed in the laboratory of Dr. Paul Leonard called DiCAST (Direct Clone Analysis and Selection Technology). Vaccinogen intends to use DiCAST to screen patient-derived biological samples acquired after those patients have gained anti-cancer immunity in the search for new anti-cancer antibodies. Vaccinogen stock is

title: Oncology Care Model
text: primary shortcoming of the payment model. A superficial monthly payment does little to prevent the unnecessary clinic visits doctors are forced to schedule in order to justify fees for actual care provided: They argue that the $160 per-beneficiary-per-month payments are insufficient to alleviate this sort of lose of revenue and the possibility of return-on-savings rarely succeeded in previous ACO models in testing. There is little scientific basis for the six months length of an episode of care that begins at the initiation of chemotherapy. While some oncology treatments take only mere weeks to complete, others can take the full six

title: South American Initiative
text: its end, this pathology continues to be one of the most important challenges of medical research. Many announcements about the discovery of a definitive cure are received with doubt and caution by the oncologists. With the creation of this project South American Initiative has designed programs and campaigns to promote information about how to prevent the most common cancer in women and men. And we will also provide proper help to most vulnerable patients by offering medicine in order to take control of chemotherapy side effects. By seeing the large number of sick pets abandoned in the streets, South American

title: Women's Health Initiative
text: post-intervention period. Specifically, the reduction of breast cancer incidence persisted throughout the early post-intervention phase, but was lost during the late post-intervention phase. Regarding endometrial cancer, although estrogen-plus-progestin use during the intervention period suggested a reduction in cancer incidence, the difference became statistically significant with additional follow-up from the extension period. These findings highlight the completely different long-term influences estrogen plus progestin have on endometrial cancer and breast cancer. According to a cumulative 18-year follow-up analysis published in 2017, it was found that, among 27,347 postmenopausal women who had originally participated in the WHI hormone therapy trials, interventions using estrogen-plus-progestin

title: Breast cancer
text: in breast cancer induced by radiation. The Cochrane collaboration (2013) states that the best quality evidence neither demonstrates a reduction in cancer specific, nor a reduction in all cause mortality from screening mammography. When less rigorous trials are added to the analysis there is a reduction in mortality due to breast cancer of 0.05% (a decrease of 1 in 2000 deaths from breast cancer over 10 years or a relative decrease of 15% from breast cancer). Screening over 10 years results in a 30% increase in rates of over-diagnosis and over-treatment (3 to 14 per 1000) and more than half

title: Talazoparib
text: received prior chemotherapy regimens for metastatic breast cancer. Patients participating in this study are randomly selected for either talazoparib or physician’s choice of chemotherapy at a 2:1 ratio to talazoparib. The target enrollment for the study was 430 patients and the estimated completion date is June 2017. In the Phase 3 EMBRACA study, talazoparib was superior to physician’s choice chemotherapy in delaying disease progression in patients with gBRCA-mutated locally advanced or metastatic breast cancer who had received up to three prior lines of chemotherapy. Talazoparib Talazoparib (trade name Talzenna, BMN-673) is an orally available poly ADP ribose polymerase (PARP) inhibitor

title: Breast cancer awareness
text: bunch of lives". For instance, a 2011 Cochrane review showed a sample of mammogram screening programs resulted in a 15% reduction in mortality rate despite over-diagnosis, indicating that mammography programs save lives regardless of over-diagnosis . Some critics say that breast cancer awareness has transformed the disease into a market-driven industry of survivorship and corporate sales pitches (; ). Corporate marketing machines promote early detection of breast cancer, while also opposing public health efforts, such as stricter environmental legislation, that might decrease the incidence rate of breast cancer. These critics believe that some of the breast cancer organizations, particularly the

title: Tivozanib
text: on overall survival in the Phase III trial. In 2016 AVEO Oncology announced the start of a second Phase III clinical study in third line advanced RCC patients. In 2016 EUSA Pharma and AVEO Oncology announced that tivozanib had been submitted to the European Medicines Agency for review under the centralised procedure. In June 2017 the EMA Scientific Committee recommended tivozanib for approval in Europe, with approval expected in September. In August 2017 the European Commission (EC) formally approved tivozanib in Europe. Tivozanib Tivozanib (trade name Fotivda) is an oral VEGF receptor tyrosine kinase inhibitor. It has completed a Phase

title: Preventive mastectomy
text: estrogen (i.e. tamoxifen, raloxifen, exemestane) can reduce the risk by about 50% but also have side effects. Prophylactic salpingo-oophorectomy reduces estrogen levels and the risk of both ovarian and breast cancer, however, the reduction in breast cancer risk is about 50% in high risk women as compared to 90% when preventive mastectomy is done. Lifestyle changes in weight, diet, exercise, avoidance of smoking, limiting alcohol) may reduce the risk to some degree. A factor that facilitates the decision to undergo a preventive mastectomy is that results of breast reconstructive surgery have improved. A 2004 Canadian study found that 70% of